FI96513B - Förfarande för framställning av terapeutiskt aktiva xantinderivat - Google Patents

Förfarande för framställning av terapeutiskt aktiva xantinderivat

Info

Publication number
FI96513B
FI96513B FI896117A FI896117A FI96513B FI 96513 B FI96513 B FI 96513B FI 896117 A FI896117 A FI 896117A FI 896117 A FI896117 A FI 896117A FI 96513 B FI96513 B FI 96513B
Authority
FI
Finland
Prior art keywords
substd
opt
alkyl
cycloalkyl
alkenyl
Prior art date
Application number
FI896117A
Other languages
English (en)
Finnish (fi)
Other versions
FI96513C (sv
FI896117A0 (sv
Inventor
Ulrike Kuefner-Muehl
Karl-Heinz Weber
Gerhard Walther
Werner Stransky
Helmut Ensinger
Guenter Schingnitz
Franz Josef Kuhn
Erich Lehr
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of FI896117A0 publication Critical patent/FI896117A0/sv
Publication of FI96513B publication Critical patent/FI96513B/sv
Application granted granted Critical
Publication of FI96513C publication Critical patent/FI96513C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI896117A 1988-12-22 1989-12-20 Förfarande för framställning av terapeutiskt aktiva xantinderivat FI96513C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE3843117 1988-12-22

Publications (3)

Publication Number Publication Date
FI896117A0 FI896117A0 (sv) 1989-12-20
FI96513B true FI96513B (sv) 1996-03-29
FI96513C FI96513C (sv) 1996-07-10

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
FI896117A FI96513C (sv) 1988-12-22 1989-12-20 Förfarande för framställning av terapeutiskt aktiva xantinderivat

Country Status (32)

Country Link
US (4) US5175291A (sv)
EP (1) EP0374808B1 (sv)
JP (1) JP2565576B2 (sv)
KR (1) KR0165666B1 (sv)
AT (1) ATE136897T1 (sv)
BG (1) BG61669B2 (sv)
BR (1) BR1100527A (sv)
CA (1) CA2006387C (sv)
CZ (1) CZ286230B6 (sv)
DD (1) DD290421A5 (sv)
DE (3) DE3843117A1 (sv)
DK (1) DK652689A (sv)
ES (1) ES2086313T3 (sv)
FI (1) FI96513C (sv)
GR (1) GR3019733T3 (sv)
HR (1) HRP940724A2 (sv)
HU (1) HU218674B (sv)
IE (1) IE74205B1 (sv)
IL (1) IL92829A (sv)
MX (1) MX9203618A (sv)
NO (1) NO173502C (sv)
NZ (1) NZ231901A (sv)
PH (2) PH31107A (sv)
PL (1) PL162877B1 (sv)
PT (1) PT92658B (sv)
RU (1) RU2057752C1 (sv)
SG (1) SG46380A1 (sv)
SI (1) SI8912423B (sv)
SK (1) SK719789A3 (sv)
UA (1) UA26427A (sv)
YU (1) YU47934B (sv)
ZA (1) ZA899881B (sv)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
EP0459702A1 (en) * 1990-05-29 1991-12-04 Zeneca Limited Azole Derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (sv) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
DE69412073T2 (de) * 1993-02-26 1999-02-18 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Xanthinderivate als adenosin-a1 rezeptor antagonisten
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
AU4527896A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Aryl thioxanthines
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6521656B1 (en) * 1998-06-01 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP1775297A3 (en) * 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
CZ20021614A3 (cs) * 1999-11-12 2002-07-17 Biogen, Inc. Polycykloalkylpuriny jako antagonisty adenosinového receptoru
ATE336492T1 (de) 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
IL161867A0 (en) 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
NZ543109A (en) * 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
JP2006515316A (ja) * 2003-05-06 2006-05-25 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストであるキサンチン誘導体
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
WO2004110379A2 (en) * 2003-06-09 2004-12-23 Endacea, Inc. A1 adenosine receptor antagonists
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
RS52455B (en) * 2004-09-01 2013-02-28 Gilead Sciences Inc. WALL HEALING PROCEDURE BY ADENOSINE A2B RECEPTOR ANTAGONISTS
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
JP5843778B2 (ja) * 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES517622A0 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz

Also Published As

Publication number Publication date
HU896736D0 (en) 1990-02-28
PL162877B1 (pl) 1994-01-31
ATE136897T1 (de) 1996-05-15
BR1100527A (pt) 2000-08-01
UA26427A (uk) 1999-08-30
PL282878A1 (en) 1992-03-09
HU218674B (hu) 2000-10-28
DD290421A5 (de) 1991-05-29
NO895168D0 (no) 1989-12-21
GR3019733T3 (en) 1996-07-31
BG61669B2 (bg) 1998-02-27
DE58909657D1 (de) 1996-05-23
NO895168L (no) 1990-06-25
RU2057752C1 (ru) 1996-04-10
ES2086313T3 (es) 1996-07-01
PH31111A (en) 1998-02-23
CZ286230B6 (cs) 2000-02-16
HRP940724A2 (en) 1997-06-30
SK279525B6 (sk) 1998-12-02
ZA899881B (en) 1991-08-28
PT92658B (pt) 1995-09-12
JPH02247180A (ja) 1990-10-02
IL92829A0 (en) 1990-09-17
KR900009646A (ko) 1990-07-05
HUT52503A (en) 1990-07-28
SK719789A3 (en) 1998-12-02
MX9203618A (es) 1992-09-01
YU47934B (sh) 1996-05-20
DE8817122U1 (de) 1993-02-04
IE74205B1 (en) 1997-07-16
DE3843117A1 (de) 1990-06-28
NZ231901A (en) 1993-12-23
CA2006387C (en) 2000-02-08
US5688802A (en) 1997-11-18
US5532368A (en) 1996-07-02
SG46380A1 (en) 1998-02-20
IE894147L (en) 1990-06-22
EP0374808A3 (de) 1991-05-15
SI8912423B (sl) 1998-12-31
FI96513C (sv) 1996-07-10
YU242389A (en) 1991-10-31
US5175291A (en) 1992-12-29
US5696124A (en) 1997-12-09
PT92658A (pt) 1990-06-29
EP0374808A2 (de) 1990-06-27
FI896117A0 (sv) 1989-12-20
EP0374808B1 (de) 1996-04-17
CA2006387A1 (en) 1990-06-22
CZ719789A3 (cs) 1999-10-13
PH31107A (en) 1998-02-23
SI8912423A (sl) 1998-04-30
DK652689D0 (da) 1989-12-21
NO173502B (no) 1993-09-13
AU4707289A (en) 1990-06-28
JP2565576B2 (ja) 1996-12-18
IL92829A (en) 1995-12-31
AU637990B2 (en) 1993-06-17
NO173502C (no) 1993-12-22
DK652689A (da) 1990-06-23
KR0165666B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
FI96513B (sv) Förfarande för framställning av terapeutiskt aktiva xantinderivat
DK148279C (da) Analogifremgangsmaade til fremstilling af 9-substituerede guaninderivater eller fysiologisk acceptable salte eller optiske isomerer deraf
KR850003533A (ko) 1,3-디옥산 유도체의 제조방법
US3950352A (en) 2,2-Dimethyl-3R-carboxy-6S-phenyl(or phenoxy)acetamido-1-oxa-4-aza-5R-bicyclo[3,2,0]heptan-7-one and processes for their production
NZ227039A (en) Benzofuran derivatives and anti-inflammatory compositions
YU47973B (sh) S-enantiomerni glutaramidi i postupak za njihovo dobijanje
KR860006470A (ko) 트리사이클릭 화합물의 제조방법
GB1108538A (en) New oxazolidine derivatives and process for their manufacture
ES449629A1 (es) Procedimiento para la preparacion de nuevos derivados de benzopiranona.
GB1525687A (en) Cephalosporin derivatives
Christensen et al. Strategy in the total synthesis of β-lactam antibiotics
ES2134345T3 (es) Derivados de 2-aciloxicefem como inhibidores de elastasa.
ATE110079T1 (de) Triazolo(1,5-c>pyrimido(1,4>azine als bronchodilatatoren.
DE3778313D1 (de) Verfahren zur isomerisierung von 2-cis-pentensaeureestern zu 2-trans-pentensaeureestern.
LYGA PART I: THE SYNTHESIS AND CARCINOGENIC ACTIVITY OF 9-METHYLBENZO (A) PYRENE, TRANS-7, 8-DIHYDROXY-9-METHYL-7, 8-DIHYDROBENZO (A) PYRENE, AND TRANS-9, 10-EPOXY-7, 8-DIHYDROXY-9-METHYL-7, 8, 9, 10-TETRAHYDROBENZO (A) PYRENE. PART II: FUNCTIONALIZATION OF THE 5'POSITION OF A NUCLEOSIDE ALDEHYDE WITH STABILIZED PHOSPHORUS YLIDES. STUDIES TOWARD THE TOTAL SYNTHESIS OF SINEFUNGIN. PART III: PYRROLO (2, 3-D) PYRIMIDINE NUCLEOSIDES.
FI894458A0 (fi) Substituerade imidazo /2,1-b/ kinazolin -5 (3h)-oner och andra liknande tricykliska foereningar.

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: BOEHRINGER INGELHEIM KG